WVE
Wave Life Sciences Ltd.
Price Chart
Latest Quote
$5.73
-0.36 (-5.91%)
Current Price
| Previous Close | $6.09 |
| Open | $6.08 |
| Day High | $6.12 |
| Day Low | $5.61 |
| Volume | 3,878,774 |
Stock Information
| Shares Outstanding | 192.40M |
| Total Debt | $15.71M |
| Cash Equivalents | $544.59M |
| Revenue | $71.80M |
| Net Income | $-183.59M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.10B |
| EPS (TTM) | $-1.05 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $573.46M |
| Sales | $71.80M |
| Income | $-183.59M |
| Book/sh | $2.76 |
| Cash/sh | $2.83 |
| Employees | 317 |
Financial Ratios
| Quick Ratio | 10.93 |
| Current Ratio | 11.26 |
| Debt/Eq | 3.07 |
Returns & Margins
| ROA | -28.23% |
| ROE | -53.10% |
| Gross Margin | -164.07% |
| Operating Margin | -81.83% |
| Profit Margin | -255.70% |
Ownership
| Insider Ownership | 15.88% |
| Institutional Ownership | 82.32% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.17 |
| P/S | 15.36 |
| P/B | 2.07 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $21.94 |
Technical Indicators
| SMA20 | $6.43 |
| SMA50 | $6.87 |
| SMA200 | $9.97 |
| RSI | 31.94 |
| ATR | 0.3793 |
| Shares Float | 90.11M |
| Short Float | 11.46% |
| Short Ratio | 4.25 |
| Volatility | -1.33 |
| Rel Volume | 0.98 |
Performance History
| Week | -12.92% |
| Month | -21.40% |
| Quarter | -56.33% |
| 6 Months | -19.75% |
| YTD | -64.08% |
| Year | -14.22% |
| 3 Years | +44.70% |
| 5 Years | -16.23% |
| 10 Years | -63.22% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $5.73 | 3,977,800 |
| 2026-06-04 | $6.09 | 3,421,000 |
| 2026-06-03 | $5.76 | 2,930,000 |
| 2026-06-02 | $5.69 | 4,440,000 |
| 2026-06-01 | $6.26 | 3,755,300 |
| 2026-05-29 | $6.58 | 3,548,600 |
| 2026-05-28 | $6.47 | 3,077,000 |
| 2026-05-27 | $6.34 | 2,567,400 |
| 2026-05-26 | $6.38 | 2,457,000 |
| 2026-05-22 | $6.38 | 2,386,300 |
| 2026-05-21 | $6.42 | 3,669,700 |
| 2026-05-20 | $6.19 | 4,644,000 |
| 2026-05-19 | $6.14 | 8,085,100 |
| 2026-05-18 | $6.40 | 6,559,200 |
| 2026-05-15 | $6.77 | 4,227,000 |
| 2026-05-14 | $6.90 | 3,169,600 |
| 2026-05-13 | $6.99 | 7,305,700 |
| 2026-05-12 | $6.79 | 4,998,400 |
| 2026-05-11 | $7.07 | 3,009,400 |
| 2026-05-08 | $7.18 | 2,550,800 |
| 2026-05-07 | $7.24 | 4,241,700 |
| 2026-05-06 | $7.29 | 4,064,200 |
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
đ° Latest News
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
Motley Fool âĸ 2026-05-31T20:16:27Z
Should WVE-006âs RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors?
Simply Wall St. âĸ 2026-05-25T11:13:08Z
Immunovantâs potential autoimmune âblockbusterâ; Waveâs RNA editing update
BioPharma Dive âĸ 2026-05-20T10:43:50Z
Growth Investors: Industry Analysts Just Upgraded Their Wave Life Sciences Ltd. (NASDAQ:WVE) Revenue Forecasts By 91%
Simply Wall St. âĸ 2026-05-08T13:41:43Z
A Look At Wave Life Sciences (WVE) Valuation After Sharp Year To Date Share Price Decline
Simply Wall St. âĸ 2026-05-03T00:17:46Z
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential
Insider Monkey âĸ 2026-05-02T17:51:45Z
Wave Life Sciences Ltd. Q1 2026 Earnings Call Summary
Moby âĸ 2026-04-29T12:30:00Z
WAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
GuruFocus.com âĸ 2026-04-29T07:05:29ZWAVE Life Sciences Q1 Earnings Call Highlights
MarketBeat âĸ 2026-04-28T19:23:57Z
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-04-28T12:45:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $42,727,000 | $108,302,000 | $113,305,000 | $3,649,000 |
| Operating Revenue | $42,727,000 | $108,302,000 | $113,305,000 | $3,649,000 |
| Expenses | ||||
| Total Expenses | $258,110,000 | $218,705,000 | $181,301,000 | $166,369,000 |
| Other Income Expense | $11,005,000 | $13,395,000 | $9,806,000 | $1,578,000 |
| Other Non Operating Income Expenses | $527,000 | $3,232,000 | $1,878,000 | $7,000 |
| Operating Expense | $258,110,000 | $218,705,000 | $181,301,000 | $166,369,000 |
| General And Administrative Expense | $75,331,000 | $59,023,000 | $51,292,000 | $50,513,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-204,378,000 | $-97,008,000 | $-57,513,000 | $-161,823,000 |
| Normalized Income | $-214,856,000 | $-107,171,000 | $-65,348,763 | $-163,126,930 |
| Net Income From Continuing And Discontinued Operation | $-204,378,000 | $-97,008,000 | $-57,513,000 | $-161,823,000 |
| Total Operating Income As Reported | $-215,383,000 | $-110,403,000 | $-67,996,000 | $-162,720,000 |
| Net Income Common Stockholders | $-204,378,000 | $-97,008,000 | $-57,513,000 | $-161,823,000 |
| Net Income | $-204,378,000 | $-97,008,000 | $-57,513,000 | $-161,823,000 |
| Net Income Including Noncontrolling Interests | $-204,378,000 | $-97,008,000 | $-57,513,000 | $-161,823,000 |
| Net Income Continuous Operations | $-204,378,000 | $-97,008,000 | $-57,513,000 | $-161,823,000 |
| Pretax Income | $-204,378,000 | $-97,008,000 | $-58,190,000 | $-161,142,000 |
| Operating Income | $-215,383,000 | $-110,403,000 | $-67,996,000 | $-162,720,000 |
| Per Share | ||||
| Diluted EPS | $-1.21 | $-0.70 | $-0.54 | $-2.05 |
| Basic EPS | $-1.21 | $-0.70 | $-0.54 | $-2.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $92,237 | $267,070 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-217,009,000 | $-111,903,000 | $-66,718,000 | $-154,177,000 |
| Total Unusual Items | $10,478,000 | $10,163,000 | $7,928,000 | $1,571,000 |
| Total Unusual Items Excluding Goodwill | $10,478,000 | $10,163,000 | $7,928,000 | $1,571,000 |
| Reconciled Depreciation | $8,852,000 | $8,663,000 | $9,206,000 | $10,114,000 |
| EBITDA (Bullshit earnings) | $-206,531,000 | $-101,740,000 | $-58,790,000 | $-152,606,000 |
| EBIT | $-215,383,000 | $-110,403,000 | $-67,996,000 | $-162,720,000 |
| Diluted Average Shares | $168,649,795 | $138,277,468 | $106,097,268 | $78,855,810 |
| Basic Average Shares | $168,649,795 | $138,277,468 | $106,097,268 | $78,855,810 |
| Diluted NI Availto Com Stockholders | $-204,378,000 | $-97,008,000 | $-57,513,000 | $-161,823,000 |
| Tax Provision | $0 | $0 | $-677,000 | $681,000 |
| Gain On Sale Of Security | $10,478,000 | $10,163,000 | $7,928,000 | $1,571,000 |
| Research And Development | $182,779,000 | $159,682,000 | $130,009,000 | $115,856,000 |
| Selling General And Administration | $75,331,000 | $59,023,000 | $51,292,000 | $50,513,000 |
| Other Gand A | $75,331,000 | $59,023,000 | $51,292,000 | $50,513,000 |
Fetched: 2026-05-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $518,357,000 | $209,515,000 | $39,630,000 | $-45,091,000 |
| Total Assets | $638,499,000 | $352,207,000 | $274,949,000 | $146,386,000 |
| Total Non Current Assets | $23,685,000 | $31,813,000 | $39,576,000 | $47,849,000 |
| Other Non Current Assets | $3,822,000 | $3,815,000 | $3,855,000 | $3,722,000 |
| Current Assets | $614,814,000 | $320,394,000 | $235,373,000 | $98,537,000 |
| Other Current Assets | $3,075,000 | $7,350,000 | $4,024,000 | $2,108,000 |
| Prepaid Assets | $8,395,000 | $9,544,000 | $9,912,000 | $7,932,000 |
| Receivables | $1,276,000 | $1,422,000 | $21,086,000 | $0 |
| Accounts Receivable | $1,276,000 | $1,422,000 | $21,086,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $602,068,000 | $302,078,000 | $200,351,000 | $88,497,000 |
| Cash And Cash Equivalents | $602,068,000 | $302,078,000 | $200,351,000 | $88,497,000 |
| Debt | ||||
| Total Debt | $17,766,000 | $25,404,000 | $32,118,000 | $37,614,000 |
| Long Term Debt And Capital Lease Obligation | $9,405,000 | $17,766,000 | $25,404,000 | $32,118,000 |
| Current Debt And Capital Lease Obligation | $8,361,000 | $7,638,000 | $6,714,000 | $5,496,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $120,142,000 | $142,692,000 | $235,319,000 | $191,477,000 |
| Total Non Current Liabilities Net Minority Interest | $25,077,000 | $31,739,000 | $48,879,000 | $119,956,000 |
| Non Current Deferred Liabilities | $7,798,000 | $6,099,000 | $15,601,000 | $79,774,000 |
| Current Liabilities | $95,065,000 | $110,953,000 | $186,440,000 | $71,521,000 |
| Current Deferred Liabilities | $44,440,000 | $65,972,000 | $150,059,000 | $31,558,000 |
| Payables And Accrued Expenses | $24,184,000 | $21,985,000 | $15,602,000 | $22,180,000 |
| Payables | $15,700,000 | $16,262,000 | $12,839,000 | $16,915,000 |
| Accounts Payable | $15,700,000 | $16,262,000 | $12,839,000 | $16,915,000 |
| Other Non Current Liabilities | - | - | - | $190,000 |
| Equity | ||||
| Common Stock Equity | $518,357,000 | $209,515,000 | $39,630,000 | $-45,091,000 |
| Total Equity Gross Minority Interest | $518,357,000 | $209,515,000 | $39,630,000 | $-45,091,000 |
| Stockholders Equity | $518,357,000 | $209,515,000 | $39,630,000 | $-45,091,000 |
| Gains Losses Not Affecting Retained Earnings | $-250,000 | $-262,000 | $-124,000 | $-29,000 |
| Other Equity Adjustments | $-250,000 | $-262,000 | $-124,000 | $-29,000 |
| Retained Earnings | $-1,326,236,000 | $-1,121,858,000 | $-1,024,850,000 | $-967,337,000 |
| Preferred Securities Outside Stock Equity | $7,874,000 | $7,874,000 | $7,874,000 | $7,874,000 |
| Other | ||||
| Ordinary Shares Number | $187,660,263 | $153,037,286 | $119,162,234 | $86,924,643 |
| Share Issued | $187,660,263 | $153,037,286 | $119,162,234 | $86,924,643 |
| Tangible Book Value | $518,357,000 | $209,515,000 | $39,630,000 | $-45,091,000 |
| Invested Capital | $518,357,000 | $209,515,000 | $39,630,000 | $-45,091,000 |
| Working Capital | $519,749,000 | $209,441,000 | $48,933,000 | $27,016,000 |
| Capital Lease Obligations | $17,766,000 | $25,404,000 | $32,118,000 | $37,614,000 |
| Total Capitalization | $518,357,000 | $209,515,000 | $39,630,000 | $-45,091,000 |
| Additional Paid In Capital | $228,365,000 | $156,454,000 | $129,237,000 | $119,442,000 |
| Capital Stock | $1,616,478,000 | $1,175,181,000 | $935,367,000 | $802,833,000 |
| Common Stock | $1,616,478,000 | $1,175,181,000 | $935,367,000 | $802,833,000 |
| Non Current Deferred Revenue | $7,798,000 | $6,099,000 | $15,601,000 | $79,774,000 |
| Long Term Capital Lease Obligation | $9,405,000 | $17,766,000 | $25,404,000 | $32,118,000 |
| Current Deferred Revenue | $44,440,000 | $65,972,000 | $150,059,000 | $31,558,000 |
| Current Capital Lease Obligation | $8,361,000 | $7,638,000 | $6,714,000 | $5,496,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $18,080,000 | $15,358,000 | $14,065,000 | $12,287,000 |
| Current Accrued Expenses | $8,484,000 | $5,723,000 | $2,763,000 | $5,265,000 |
| Net PPE | $19,863,000 | $27,998,000 | $35,721,000 | $44,127,000 |
| Accumulated Depreciation | $-49,522,000 | $-46,329,000 | $-42,709,000 | $-37,846,000 |
| Gross PPE | $69,385,000 | $74,327,000 | $78,430,000 | $81,973,000 |
| Leases | $28,936,000 | $28,885,000 | $28,525,000 | $28,413,000 |
| Construction In Progress | $598,000 | $349,000 | $294,000 | $318,000 |
| Other Properties | $12,458,000 | $17,870,000 | $22,637,000 | $26,843,000 |
| Machinery Furniture Equipment | $27,393,000 | $27,223,000 | $26,974,000 | $26,399,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-05-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-188,211,000 | $-151,964,000 | $-20,546,000 | $-129,142,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-187,493,000 | $-151,026,000 | $-19,431,000 | $-127,781,000 |
| Cash Flow From Continuing Operating Activities | $-187,493,000 | $-151,026,000 | $-19,431,000 | $-127,781,000 |
| Operating Gains Losses | - | - | - | $12,000 |
| Investing Activities | ||||
| Capital Expenditure | $-718,000 | $-938,000 | $-1,115,000 | $-1,361,000 |
| Investing Cash Flow | $-718,000 | $-938,000 | $-1,115,000 | $-1,255,000 |
| Cash Flow From Continuing Investing Activities | $-718,000 | $-938,000 | $-1,115,000 | $-1,255,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $472,486,000 | $236,176,000 | $131,277,000 | $52,325,000 |
| Financing Cash Flow | $488,235,000 | $253,890,000 | $132,534,000 | $67,188,000 |
| Cash Flow From Continuing Financing Activities | $488,235,000 | $253,890,000 | $132,534,000 | $67,188,000 |
| Net Common Stock Issuance | $472,486,000 | $236,176,000 | $131,277,000 | $52,325,000 |
| Common Stock Issuance | $472,486,000 | $236,176,000 | $131,277,000 | $52,325,000 |
| Other | ||||
| End Cash Position | $605,874,000 | $305,838,000 | $204,050,000 | $92,157,000 |
| Beginning Cash Position | $305,838,000 | $204,050,000 | $92,157,000 | $154,215,000 |
| Effect Of Exchange Rate Changes | $12,000 | $-138,000 | $-95,000 | $-210,000 |
| Changes In Cash | $300,024,000 | $101,926,000 | $111,988,000 | $-61,848,000 |
| Proceeds From Stock Option Exercised | $15,749,000 | $17,714,000 | $1,257,000 | $14,863,000 |
| Net PPE Purchase And Sale | $-718,000 | $-938,000 | $-1,115,000 | $-1,255,000 |
| Purchase Of PPE | $-718,000 | $-938,000 | $-1,115,000 | $-1,361,000 |
| Change In Working Capital | $-16,940,000 | $-75,822,000 | $19,081,000 | $6,722,000 |
| Change In Other Working Capital | $-19,833,000 | $-93,589,000 | $54,328,000 | $-3,245,000 |
| Change In Other Current Liabilities | $-7,638,000 | $-6,714,000 | $-5,686,000 | $-4,118,000 |
| Change In Other Current Assets | $4,314,000 | $-3,225,000 | $-2,010,000 | $3,394,000 |
| Change In Payables And Accrued Expense | $4,922,000 | $7,674,000 | $-4,485,000 | $12,039,000 |
| Change In Accrued Expense | $5,483,000 | $4,253,000 | $-724,000 | $2,691,000 |
| Change In Payable | $-561,000 | $3,421,000 | $-3,761,000 | $9,348,000 |
| Change In Account Payable | $-561,000 | $3,421,000 | $-3,761,000 | $9,348,000 |
| Change In Prepaid Assets | $1,149,000 | $368,000 | $-1,980,000 | $-1,348,000 |
| Change In Receivables | $146,000 | $19,664,000 | $-21,086,000 | $0 |
| Changes In Account Receivables | $146,000 | $19,664,000 | $-21,086,000 | $0 |
| Stock Based Compensation | $24,973,000 | $13,141,000 | $9,795,000 | $17,194,000 |
| Depreciation Amortization Depletion | $8,852,000 | $8,663,000 | $9,206,000 | $10,114,000 |
| Depreciation And Amortization | $8,852,000 | $8,663,000 | $9,206,000 | $10,114,000 |
| Depreciation | $8,852,000 | $8,663,000 | $9,206,000 | $10,114,000 |
| Net Income From Continuing Operations | $-204,378,000 | $-97,008,000 | $-57,513,000 | $-161,823,000 |
| Net Investment Purchase And Sale | - | $0 | $0 | $0 |
| Sale Of Investment | - | $0 | $0 | $75,044,000 |
| Purchase Of Investment | - | $0 | $0 | $-75,044,000 |
| Sale Of PPE | - | $0 | $0 | $106,000 |
| Gain Loss On Sale Of PPE | - | $0 | $0 | $12,000 |
Fetched: 2026-05-30